Quick viewing(Text Mode)

Interactions with PBC Agents

Interactions with PBC Agents

www.hep-druginteractions.org

Interactions with PBC Agents

Charts created August 2019. Full information available at www.hep-druginteractions.org Page 1 of 4 Please note that if a is not listed it cannot automatically be assumed it is safe to coadminister.

Obeticholic Ursodeoxycholic Obeticholic Ursodeoxycholic Obeticholic Ursodeoxycholic Acid Acid Acid Acid Acid Acid Anaesthetics & Muscle Relaxants Antibacterials (continued)   Dapsone    Cisatracurium   Delamanid     Ertapenem             Ethambutol        Thiopental   Gentamicin    

Tizanidine            Linezolid      Lymecycline         Meropenem      Methenamine    distribution. for   Metronidazole      Moxifloxacin     Nitrofurantoin   Diamorphine        Norfloxacin     Moclobemide   V      Piperacillin     Pivmecillinam       Pyrazinamide      distribution. for Not only. use ersonal       Rifapentine      Spectinomycin          Antidiabetics Sulfadiazine   (Dipyrone)     Tazobactam         Telithromycin     Temocillin    

Oxycodone    Not only. use For personal for distribution.     Ticarcillin     (Meperidine)  /Sulfamethoxazole             (Glyburide)  , Antiplatelet & Fibrinolytic   Anthelmintics Acenocoumarol  Albendazole   Anagrelide  nal use only. Not for distribution. For p for distribution. Not only. use nal   Apixaban    Oxamniquine   Clopidogrel    Praziquantel  Dabigatran    Pyrantel   r perso Dalteparin     Danaparoid   Antiarrhythmics   Dipyridamole      Eltrombopag       Enoxaparin      Fluindione   Fondaparinux    Heparin     (Lignocaine)    Prasugrel      Rivaroxaban   Streptokinase       Ticagrelor   Anidulafungin   Antibacterials Ticlodipine   Caspofungin   Amikacin   Tinazaparin   Fluconazole   Amoxicillin    Flucytosine   Ampicillin     Azithromycin    Isavuconazole   Aztreonam       Eslicarbazepine       For personal use only. Not for distribution. Fo for distribution. Not only. use For personal For personal use only. Not for distribution. For personal use only. Not Not only. use For personal for distribution. Not only. use For personal     Capreomycin       Cefaclor   Posaconazole  Cefadroxil     Terbinafine   Cefalexin     Voriconazole  Cefazolin     Cefixime     Cefotaxime      Ceftaroline     Ceftazidine     Ceftriazone     Cefuroxime     Chloramphenicol             Clavulanic acid   (Divalproex)     Cloxacillin    

Key to symbols Notes  Further information is available at © Liverpool Drug Interactions Group,  These should not be coadministered www.hep-druginteractions.org University of Liverpool, Research Labs, Potential clinically significant interaction that is likely to require additional  Predicted interactions are based on known 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF  monitoring, alteration of drug dosage or timing of administration metabolic pathways and routes of . We aim to ensure that information is accurate and consistent with current knowledge Potential interaction likely to be of weak intensity. Additional  Caution is required in patients with hepatic and practice. However, the University of Liverpool and its servants or agents shall action/monitoring or dosage adjustment is unlikely to be required impairment as this may also increase drug levels not be responsible or in any way liable for the continued currency of information in and require dose modification. this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude  No clinically significant interaction expected  Where advice differs between countries, the liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

charts reflect the more cautious option.

www.hep-druginteractions.org

Interactions with PBC Agents

Charts created August 2019. Full information available at www.hep-druginteractions.org Page 2 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

Obeticholic Ursodeoxycholic Obeticholic Ursodeoxycholic Obeticholic Ursodeoxycholic Acid Acid Acid Acid Acid Acid Antivirals Therapies Aciclovir   Abiraterone       Acalabrutinib    Brivudine   Anastrozole    Cidofovir   Avelumab     Foscarnet   Axitinib     Oseltamivir   Bevacizumab     Blinatumomab  

Rimantadine     Valaciclovir   Bortezomib     Zanamivir   Bosutinib     Brentuximab vedotin   //   Capecitabine       Carboplatin     Cetuximab     for distribution. for Chlorambucil  Antimigraine Agents Bromperidol   Cisplatin       Daratumumab   Dihydoergotamine     Dasatinib       Doxorubicin     Erlotinib      Estramustine  Methylergonovine    Etoposide       Everolimus   

ersonal use only. Not for distribution. for Not only. use ersonal   Exemestane      Fludarabine     (oral)  Gefitinib   Zolmiptriptan   Midazolam (parenteral)  Gemcitabine   Antiprotozoals   Idarubicin  Amodiaquine   Artemether     Ipilimumab       Irinotecan   Artesunate     Ixazomib   Atovaquone    Lapatinib   Chloroquine   

Dihydroartemisinin     Not only. use For personal for distribution. Letrozole   Mercaptopurine   Doxycycline   Beta Blockers   Halofantrine    Hydroxychloroquine     Mitoxantrone   Lumefantrine   Carvediol  Nilotinib      Niraparib      Nivolumab   Primaquine  Obinutuzumab  

nal use only. Not for distribution. For p for distribution. Not only. use nal   Proguanil    Ofatumumab   Pyrimethamine    Olaratumab     Oxaliplatin   r perso stibogluconate   Propanolol   Sulfadoxine     Panitumumab   /Neuroleptics  Pembrolizumab     Bisphosphonates Rituximab     Alendronic acid   Sorafenib    Clodronate   Sunitinib     Ibandronic acid    Temsirolimus   Pamidronate     Vinblastine   Risedronate    Vincristine    Bronchodilators Vinorelbine     Contraceptives and Hormone Replacements     Ipatropium     Dienogest    Montelukast      Omalizumab   Estradiol             Etonogestrel (implant)       Etonogestrel (vaginal ring)    Tiotropium   For personal use only. Not for distribution. Fo for distribution. Not only. use For personal   Not only. use For personal for distribution. Not only. use For personal Levonorgestrel (COC)   Blockers   Levonorgestrel      (Emergency Contraception)

Risperidone   Levonorgestrel (HRT)   Sulpride   Levonorgestrel (implant)    Levonorgestrel (IUD)   Tiapride   Levonorgestrel (POP)     Medroxyprogesterone (depot)      Medroxyprogesterone (oral)   Zuclopentixol   Norethisterone (norethindrone) 

Key to symbols Notes  Further information is available at © Liverpool Drug Interactions Group,  These drugs should not be coadministered www.hep-druginteractions.org University of Liverpool, Pharmacology Research Labs, Potential clinically significant interaction that is likely to require additional  Predicted interactions are based on known 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF  monitoring, alteration of drug dosage or timing of administration metabolic pathways and routes of clearance. We aim to ensure that information is accurate and consistent with current knowledge Potential interaction likely to be of weak intensity. Additional  Caution is required in patients with hepatic and practice. However, the University of Liverpool and its servants or agents shall action/monitoring or dosage adjustment is unlikely to be required impairment as this may also increase drug levels not be responsible or in any way liable for the continued currency of information in and require dose modification. this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude  No clinically significant interaction expected  Where advice differs between countries, the liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

charts reflect the more cautious option.

www.hep-druginteractions.org

Interactions with PBC Agents

Charts created August 2019. Full information available at www.hep-druginteractions.org Page 3 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

Obeticholic Ursodeoxycholic Obeticholic Ursodeoxycho Obeticholic Ursodeoxycholic Acid Acid Acid lic Acid Acid Acid Agents Herbals/Supplements/Vitamins / Failure Agents   Aloe vera       Ascorbic acid (Vitamin C)   Aliskiren   Vardenafil   Black cohosh (A. racemosa)     Gastrointestinal Agents Cat’s claw (U. tomentosa)     Aluminium hydroxide   Colecalciferol (Vitamin D3)   Azilsartan     Alverine citrate   Cyanocobalamin (B12) Benazepril   Antacids   Diosmin  

Bendroflumethiazide     Echinacea     Eucalyptus globulus       Folic acid   Candesartan     Captopril     (Z. officinale)               distribution. for   Goldenseal (H. canadensis)   Cilazapril   Esomeprazole   Grape seed extract       Grapefruit juice       Green tea (C. sinensis)    Hyoscine   Inula racemosa   Enalapril   Ispaghula husk         Iron supplements   Epoprostenol   kava (P. methysticum)   Lansoprazole   Eprosartan   Milk thistle     Fosinopril     distribution. for Not only. use ersonal Retinol (Vitamin A)       Riboflavin (Vitamin B2)   Hydralazine     Serenoa repens       St John’s wort     Thiamine (Vitamin B1)     Methylcellulose   ()         Irbesartan     Vitamin E     HIV Drugs Ivabradine     Entry/Integrase Inhibitors

Pantoprazole   Bictegravir/FTC/TAF   Not only. use For personal for distribution.   Dolutegravir     Rabeprazole  Dolutegravir/rilpivirine       Elvitegravir/cobi /FTC/TAF     Senna   Elvitegravir/cobi/FTC/TDF     Simeticone   Ibalizumab-uiyk       Maraviroc   Moxonidine     Raltegravir   nal use only. Not for distribution. For p for distribution. Not only. use nal Olmesartan   NNRTIs Hepatitis Drugs Perindopril   Adefovir  Doravirine     Daclatasvir   Doravirine/3TC/TDF   r perso Quinapril  Elbasvir/Grazoprevir    Glecaprevir/Pibrentasvir   Etravirine   Ramipril   Entecavir   Lamivudine   Rilpivirine     Ledipasvir/Sofosbuvir   Rilpivirine/dolutegravir     OBV/PTV/r   Rilpivirine/FTC/TAF    OBV/PTV/r + Dasabuvir   NRTIs Sildenafil   Peginterferon alfa-2a   Abacavir     Peginterferon alfa-2b   Didanosine   Tadalafil   Ribavirin   Emtricitabine (FTC)     Simeprevir   Emtricitabine + TAF     Emtricitabine + TDF   Sofosbuvir (SOF)   Trandolapril   Lamivudine   SOF/Velpatasvir    SOF/Velpatasvir/Voxilaprevir   Stavudine   Valsartan   Telbivudine   Tenofovir-DF     Tenofovir alafenamide (TAF)   Zidovudine   Zofenopril   Tenofovir-DF   Protease Inhibitors Atazanavir alone   Atazanavir/cobicistat   Atazanavir +   For personal use only. Not for distribution. Fo for distribution. Not only. use For personal Darunavir/cobicistat   Not only. use For personal for distribution. Not only. use For personal Darunavir/cobi/FTC/TAF   Darunavir + ritonavir   Fosamprenavir    Lopinavir  Ritonavir   Saquinavir  Tipranavir 

Key to symbols Notes  Further information is available at © Liverpool Drug Interactions Group,  These drugs should not be coadministered www.hep-druginteractions.org University of Liverpool, Pharmacology Research Labs, Potential clinically significant interaction that is likely to require additional  Predicted interactions are based on known 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF  monitoring, alteration of drug dosage or timing of administration metabolic pathways and routes of clearance. We aim to ensure that information is accurate and consistent with current knowledge Potential interaction likely to be of weak intensity. Additional  Caution is required in patients with hepatic and practice. However, the University of Liverpool and its servants or agents shall action/monitoring or dosage adjustment is unlikely to be required impairment as this may also increase drug levels not be responsible or in any way liable for the continued currency of information in and require dose modification. this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude  No clinically significant interaction expected  Where advice differs between countries, the liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

charts reflect the more cautious option.

www.hep-druginteractions.org

Interactions with PBC Agents

Charts created August 2019. Full information available at www.hep-druginteractions.org Page 4 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

Obeticholic Ursodeoxycholic Obeticholic Ursodeoxycholic Acid Acid Acid Acid Illicit/Recreational Other Drugs         Acitretin  Ecstasy (MDMA)  Activated charcoal   GHB (Gamma-hydroxybutyrate)   Allopurinol   LSD (Lysergic acid diethylamide)     

Methamphetamine    (PCP)  Benralizumab   Immunosuppressants     Alemtuzumab    Azathioprine   Brinzolamide   Basiliximab     Brodalumab   distribution. for Calcitonin     Calcium carbimide   Eculizumab   Calcium resonium   Etanercept   Carbimazole   Fingolimod    Lenalidomide   Cilostazol   Mycophenolate  Clomifene        Colestyramine 

Tacrolimus  distribution. for Not only. use ersonal   Lipid Lowering Agents  Atorvastatin     Bezafibrate   Darbepoetin   Ezetimibe  Deferiprone   Fenofibrate   Denosumab   Fish oils   Dexamfetamine  Fluvastatin       

Pitavastatin   Dorzolamide   Not only. use For personal for distribution. Pravastatin   Dupilumab   Rosuvastatin   Eliglustat     Epoetin alfa   Oxytocics Etelcalcetide    (ergonovine)   Febuxostat Filgrastim     Flibanserin 

Misoprostol  For p for distribution. Not only. use nal Gadopentetate (gadolinium)   Agents phenylbutyrate   Benztropine   Goserelin     r perso    Isotretinoin  Lanreotide   Rasagline      PBC Agents /   Obeticholic acid    Ursodeoxycholic acid              Ciclesonide     Clobetasol (topical)     Clobetasone (topical)           Neostigmine   Flunisolide     Fluticasone   Nusinersan   Ocrelizumab   (topical)   For personal use only. Not for distribution. Fo for distribution. Not only. use For personal   Not only. use For personal for distribution. Not only. use For personal Penicillamine               Triamcinolone     Urological Agents     Protamine sulphate   Desmopressin        Raloxifene     Sevelamer     Strontium ranelate     Thalidomide     Tranexamic acid      

Key to symbols Notes  Further information is available at © Liverpool Drug Interactions Group,  These drugs should not be coadministered www.hep-druginteractions.org University of Liverpool, Pharmacology Research Labs, Potential clinically significant interaction that is likely to require additional  Predicted interactions are based on known 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF  monitoring, alteration of drug dosage or timing of administration metabolic pathways and routes of clearance. We aim to ensure that information is accurate and consistent with current knowledge Potential interaction likely to be of weak intensity. Additional  Caution is required in patients with hepatic and practice. However, the University of Liverpool and its servants or agents shall action/monitoring or dosage adjustment is unlikely to be required impairment as this may also increase drug levels not be responsible or in any way liable for the continued currency of information in and require dose modification. this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude  No clinically significant interaction expected  Where advice differs between countries, the liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

charts reflect the more cautious option.